BRPI0815203B1 - gel contendo pirfenidona - Google Patents
gel contendo pirfenidona Download PDFInfo
- Publication number
- BRPI0815203B1 BRPI0815203B1 BRPI0815203-9A BRPI0815203A BRPI0815203B1 BR PI0815203 B1 BRPI0815203 B1 BR PI0815203B1 BR PI0815203 A BRPI0815203 A BR PI0815203A BR PI0815203 B1 BRPI0815203 B1 BR PI0815203B1
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- preservative
- composition
- fact
- viscous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
| Componente | Quantidade (g) | % |
| Pirfenidona | 8 | 8 |
| Agente viscoso | 0,5 | 0,5 |
| Solubilizante | 20 | 20 |
| Solubilizante não-iônico | 11,5 | 11,5 |
| Agente de conservação | 0,5 | 0,5 |
| Neutralizador | 0,5 | 0,5 |
| Água purificada até | 100 | 59 |
| Componente | Quantidade (g) |
| Pirfenidona | 8 |
| Carbômero | 0,5 |
| N-metilpirrolidona | 20 |
| Macrogol glicerol Hidróxi estearato 40 | 11,5 |
| Carbamato de diazolidinilureia e Iodopropinil-butila | 0,5 |
| Trietanolamina | 0,5 |
| Água purificada até | 100 |
Claims (5)
- REIVINDICAÇÕES1. Composição em gel, caracterizada pelo fato de que consiste em:
- 2 a 12% de pirfenidona;0,4 a 1,2% de um agente viscoso,10 a 30% de um agente de solubilização,5 a 15% de um agente de solubilização não-iônico,0,2 a 1% de um agente de conservação,0,4 a 1,2% de um agente de neutralização, e o restante de água purificada.2. Composição, de acordo com a reivindicação 1, caracterizada pelo fato de que inclui:pirfenidona a 8%;0,5% do agente viscoso,20% do agente de solubilização,11,5% do agente de solubilização não-iônico,0,5% do agente de conservação,0,5% do agente de neutralização, e o restante de água purificada.
- 3. Composição, de acordo com a reivindicação 1, caracterizada pelo fato de que:o agente viscoso é selecionado a partir de Carbômero 940®, Ultrex 10®, derivados de celulose; gomas; polioxâmeros; álcool etílico e propilenoglicol;o agente de conservação é selecionado a partir de um grupo que consiste em diazolinidil ureia, carbamato de iodopropinilbutila; metilparabeno, propilparabeno e uma mistura desses compostos; e o agente de neutralização é selecionado a partir de um grupo de aminas alifáticas primárias, secundárias e terciárias do tipoPetição 870190101121, de 09/10/2019, pág. 9/152/2 de mono-, bi- e trietanolamina, e de hidróxidos de metal alcalino, tal como hidróxido de sódio.
- 4. Composição, de acordo com a reivindicação 1, caracterizada pelo fato de que:o agente viscoso é o Carbômero 940®, o agente de solubilização é a N-metilpirrolidona;o agente de conservação é a N-diazolidinil ureia e carbamato de iodopropinil-butila; e o agente de neutralização é a trietanolamina.
- 5. Processo para fabricação da composição, como definida na reivindicação 1, caracterizado pelo fato de que inclui as etapas que se seguem:(a) Misturar 50% do total de água a ser usado com o agente viscoso, permitindo a umectação completa do agente viscoso;(b) Misturar separadamente e com agitação constante as pirfeni-dona com o agente de solubilização;(c) Dissolver separadamente o agente solubilizante nãoiônico em 25% da água a ser usada a 40°C, uma vez dissolvido, é adicionado 15% do total da água;(d) Adicionar à solução da parte (c) a mistura da parte (b), agitando até que a misture se torne homogênea;(e) Diluir o agente de neutralização em 10% do total da água a ser usada, agitar até que a mistura se torne homogênea; e (f) Adicionar com agitação constante e homogeneizada em cada adição a mistura da parte (a) a solução da parte (d); o agente de conservação e a solução da parte (e).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007009796A MX2007009796A (es) | 2007-08-14 | 2007-08-14 | Gel conteniendo pirfenidona. |
| MXMX/A/2007/009796 | 2007-08-14 | ||
| PCT/MX2008/000107 WO2009022899A1 (es) | 2007-08-14 | 2008-08-14 | Gel conteniendo pirfenidona |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0815203A2 BRPI0815203A2 (pt) | 2017-03-28 |
| BRPI0815203B1 true BRPI0815203B1 (pt) | 2020-05-05 |
| BRPI0815203B8 BRPI0815203B8 (pt) | 2021-05-25 |
Family
ID=40350871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815203A BRPI0815203B8 (pt) | 2007-08-14 | 2008-08-14 | composição em gel contendo pirfenidona, e seu processo de fabricação |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8492412B2 (pt) |
| EP (1) | EP2177220B1 (pt) |
| JP (1) | JP5542053B2 (pt) |
| KR (1) | KR101235968B1 (pt) |
| CN (2) | CN104771355A (pt) |
| BR (1) | BRPI0815203B8 (pt) |
| CA (1) | CA2696335C (pt) |
| CO (1) | CO6180448A2 (pt) |
| EC (1) | ECSP109960A (pt) |
| HK (1) | HK1211464A1 (pt) |
| MX (1) | MX2007009796A (pt) |
| SG (1) | SG183732A1 (pt) |
| WO (1) | WO2009022899A1 (pt) |
| ZA (1) | ZA201000918B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| ES2567283T3 (es) | 2008-06-03 | 2016-04-21 | Intermune, Inc. | Compuestos y métodos para tratar trastornos inflamatorios y fibróticos |
| CN101972225A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的凝胶组合物 |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| AU2012212269B2 (en) | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| EP4491180A1 (en) | 2014-01-10 | 2025-01-15 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| MX368750B (es) * | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
| US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
| US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
| US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| DE2366349C2 (de) | 1972-12-18 | 1986-03-27 | Affiliated Medical Research Inc., Princeton, N.J. | Verfahren zur Herstellung von 5-Methyl-1-phenyl-2-(1H)-pyridon |
| ZA757570B (en) * | 1974-12-09 | 1977-07-27 | Affiliated Med Res | A useful n-substituted pyridone |
| US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
| JPS51128438A (en) | 1975-04-26 | 1976-11-09 | Yamanouchi Pharmaceut Co Ltd | An antibacterial drug against fish diseases |
| SE430609B (sv) | 1976-12-21 | 1983-11-28 | Sca Development Ab | Sett att ur cellulosaderivat framstella absorberande material |
| US4376118A (en) * | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
| JPS60214732A (ja) * | 1984-04-05 | 1985-10-28 | Grelan Pharmaceut Co Ltd | 外用貼付剤 |
| JP2618256B2 (ja) * | 1988-03-31 | 1997-06-11 | ポーラ化成工業株式会社 | 消炎鎮痛外用剤 |
| US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| ES2183839T3 (es) | 1993-05-07 | 2003-04-01 | Solomon B Margolin | Composiciones y procedimiento de reparacion y de prevencion de lesiones del tipo de fibrosis. |
| US5436241A (en) * | 1994-01-14 | 1995-07-25 | Bristol-Myers Squibb Company | Topical anti-inflammatory compositions containing piroxicam |
| SI0868183T1 (en) * | 1995-12-21 | 2002-04-30 | Pfizer Inc. | Injectable quinolone formulations |
| DE19639816A1 (de) * | 1996-09-27 | 1998-04-02 | Hoechst Ag | Antimykotische Mittel mit hoher Wirkstofffreisetzung |
| US5958420A (en) * | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
| US6365131B1 (en) * | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
| ATE266405T1 (de) | 1998-03-17 | 2004-05-15 | Solomon B Margolin | Topische antiseptische zusammenstellungen und methoden |
| GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
| EP1113798B1 (en) * | 1998-09-18 | 2003-01-02 | Mepha AG | Topical formulation of alkyl-, phenyl-pyridone |
| US20020028784A1 (en) | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
| IN191090B (pt) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
| WO2002060446A1 (fr) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif |
| US20030103941A1 (en) | 2001-10-09 | 2003-06-05 | Crombleholme Timothy M. | Materials and methods for preventing or reducing scar formation |
| CH696420A5 (de) | 2002-09-13 | 2007-06-15 | Mepha Ag | Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung. |
| JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
| WO2004073713A1 (ja) | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | ピルフェニドンのゲル剤 |
| WO2004078207A1 (en) | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| AU2003225670A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
| WO2004089283A2 (en) | 2003-04-04 | 2004-10-21 | Intermune, Inc. | Compositions and methods for treating viral infections |
| EP1638625A4 (en) | 2003-05-23 | 2009-08-19 | David M Ott | ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM |
| WO2005000227A2 (en) | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| ES2398912T3 (es) | 2003-10-14 | 2013-03-22 | F. Hoffmann-La Roche Ltd. | Ácido carboxílico macrocíclico y compuesto de acilsulfonamida como inhibidor de la replicación del virus de la hepatitis C |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| WO2005067454A2 (en) | 2003-12-23 | 2005-07-28 | Valeant Pharmaceuticals North America | Combination therapy for treating hepatitis c virus infection |
| CN100542532C (zh) | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
| US20060051339A1 (en) | 2004-09-08 | 2006-03-09 | Sivak Hannah N | Composition for treatment of oily skin and acne prevention and methods of making and using same |
| US20060115503A1 (en) | 2004-11-30 | 2006-06-01 | Goyal Muna C | Composition, system and method for treatment of skin |
| US7728013B2 (en) | 2005-05-10 | 2010-06-01 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
| EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| EP2426134A3 (en) | 2005-11-23 | 2012-07-04 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
| EP1973525B1 (en) * | 2005-12-05 | 2014-04-30 | RBA Pharma Inc. | Emulsion-containing medical articles |
| CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
| CN101687789A (zh) | 2007-02-12 | 2010-03-31 | 因特蒙公司 | C型肝炎病毒复制的新颖抑制剂 |
| WO2008107873A1 (en) | 2007-03-02 | 2008-09-12 | Yeda Res & Dev | Mercaptopurine derivatives as anticancer agents |
| US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| CN104892498A (zh) | 2007-06-20 | 2015-09-09 | 奥斯拜客斯制药有限公司 | 作为纤维化抑制剂的取代的n-芳基吡啶酮 |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| US20090137354A1 (en) | 2007-11-27 | 2009-05-28 | Shimano Inc. | Bicycle rear derailleur |
| WO2009075881A2 (en) | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| US20100256031A1 (en) | 2008-10-10 | 2010-10-07 | Jeffrey Wu | Shine control cleanser |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| CN101972236A (zh) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
| CN101972225A (zh) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的凝胶组合物 |
| AU2012212269B2 (en) | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| ES2742273T3 (es) | 2011-02-15 | 2020-02-13 | Aclaris Therapeutics Inc | Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea |
| CN102670632A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 吡非尼酮在抑制皮肤瘢痕形成的医药用途 |
| CN102670600A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用 |
| US9241921B2 (en) | 2011-05-02 | 2016-01-26 | Pankaj Modi | Photosensitizer composition for treating skin disorders |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| CN102488660A (zh) | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| WO2013181691A1 (en) | 2012-06-04 | 2013-12-12 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor |
| CA2875541A1 (en) | 2012-06-12 | 2013-12-19 | Patrick F. Smith | Combination of therapeutic agents for treating hcv infection |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| JP6473134B2 (ja) | 2013-03-15 | 2019-02-20 | メディシス ファーマシューティカル コーポレイション | フルニソリドの局所用組成物および治療方法 |
| US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| MX352342B (es) | 2013-07-12 | 2017-11-22 | Moleculas Naturales S A De C V Star | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos. |
| CN103550242B (zh) | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
| GB201508419D0 (en) | 2015-05-15 | 2015-07-01 | Cambridge Entpr Ltd | Detection of T cell exhaustion or lack of T cell costimulation and uses thereof |
| HK1255224A1 (en) | 2015-12-16 | 2019-08-09 | Daiichi Sankyo Company, Limited | Wound treatment agent |
| JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
| MX364040B (es) | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| JP2023521887A (ja) | 2020-04-14 | 2023-05-25 | エクスカリバー ファーマシューティカルズ,インク. | コロナウイルス治療のためのピルフェニドン |
-
2007
- 2007-08-14 MX MX2007009796A patent/MX2007009796A/es active IP Right Grant
-
2008
- 2008-08-14 CN CN201510091398.9A patent/CN104771355A/zh active Pending
- 2008-08-14 CA CA2696335A patent/CA2696335C/en active Active
- 2008-08-14 US US12/673,304 patent/US8492412B2/en active Active
- 2008-08-14 BR BRPI0815203A patent/BRPI0815203B8/pt not_active IP Right Cessation
- 2008-08-14 KR KR1020107003346A patent/KR101235968B1/ko active Active
- 2008-08-14 JP JP2010520954A patent/JP5542053B2/ja active Active
- 2008-08-14 WO PCT/MX2008/000107 patent/WO2009022899A1/es not_active Ceased
- 2008-08-14 CN CN200880103142A patent/CN101808641A/zh active Pending
- 2008-08-14 SG SG2012060505A patent/SG183732A1/en unknown
- 2008-08-14 EP EP08827482.4A patent/EP2177220B1/en active Active
-
2010
- 2010-02-08 ZA ZA2010/00918A patent/ZA201000918B/en unknown
- 2010-02-11 CO CO10015040A patent/CO6180448A2/es active IP Right Grant
- 2010-02-12 EC EC2010009960A patent/ECSP109960A/es unknown
- 2010-10-28 HK HK15112082.7A patent/HK1211464A1/xx unknown
-
2013
- 2013-05-14 US US13/893,626 patent/US20130245073A1/en not_active Abandoned
-
2017
- 2017-02-17 US US15/435,494 patent/US10376500B2/en active Active
-
2019
- 2019-06-24 US US16/450,150 patent/US11083719B2/en active Active
-
2021
- 2021-07-30 US US17/390,368 patent/US11779574B2/en active Active
-
2023
- 2023-08-30 US US18/458,390 patent/US20240238262A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8492412B2 (en) | 2013-07-23 |
| US10376500B2 (en) | 2019-08-13 |
| MX2007009796A (es) | 2009-02-25 |
| EP2177220B1 (en) | 2019-05-29 |
| SG183732A1 (en) | 2012-09-27 |
| CN101808641A (zh) | 2010-08-18 |
| JP2010536747A (ja) | 2010-12-02 |
| US11083719B2 (en) | 2021-08-10 |
| US20240238262A1 (en) | 2024-07-18 |
| BRPI0815203B8 (pt) | 2021-05-25 |
| US11779574B2 (en) | 2023-10-10 |
| JP5542053B2 (ja) | 2014-07-09 |
| CN104771355A (zh) | 2015-07-15 |
| US20170216268A1 (en) | 2017-08-03 |
| WO2009022899A1 (es) | 2009-02-19 |
| BRPI0815203A2 (pt) | 2017-03-28 |
| KR101235968B1 (ko) | 2013-02-21 |
| EP2177220A4 (en) | 2013-09-11 |
| ZA201000918B (en) | 2011-04-28 |
| HK1211464A1 (en) | 2016-05-27 |
| US20130245073A1 (en) | 2013-09-19 |
| US20110224265A1 (en) | 2011-09-15 |
| US20200016138A1 (en) | 2020-01-16 |
| CA2696335C (en) | 2014-03-04 |
| CO6180448A2 (es) | 2010-07-19 |
| CA2696335A1 (en) | 2009-02-19 |
| EP2177220A1 (en) | 2010-04-21 |
| US20220016096A1 (en) | 2022-01-20 |
| WO2009022899A8 (es) | 2009-09-11 |
| ECSP109960A (es) | 2010-04-30 |
| KR20100040319A (ko) | 2010-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815203B1 (pt) | gel contendo pirfenidona | |
| DE3119017A1 (de) | Entzuendungshemmende und analgetische gel-zusammensetzungen | |
| PT98790B (pt) | Processo para a preparacao de uma composicao farmaceutica contendo florfenicol | |
| JP5037121B2 (ja) | 局所的適用のための爪再構成組成物 | |
| BRPI0312814B1 (pt) | levamisol / avermectinas ou similares em solvente de pirrolidona | |
| CN104258427A (zh) | 用于创面超声诊断的杀菌型医用超声耦合剂及其制备方法 | |
| JP2013519695A5 (pt) | ||
| DE102007032158A1 (de) | Antitumormittel | |
| CN115919683A (zh) | 一种透明组合物及其制备方法和应用 | |
| JPWO2016080495A1 (ja) | 外用組成物 | |
| DE2104851A1 (pt) | ||
| US2448180A (en) | Medicinal composition | |
| CN104173321A (zh) | 制备通过外用贴剂给药的、具有消炎镇痛活性的药物组合物的方法,及以此获得的组合物 | |
| HK1143546A (en) | Gel containing pirfenidone | |
| JPS59122420A (ja) | 局所軟膏剤 | |
| CN106943348A (zh) | 一种乳酸依沙吖啶油膜剂及其制备方法 | |
| CN105997536A (zh) | 一种动物医用脱毛剂及其制备方法 | |
| DE1815466A1 (de) | Verfahren zur Herstellung von neuen 5-Nitrofuryl-derivaten | |
| DE102011013524A1 (de) | Mittel EXPORTAL mit gastroprotektiver (antiulceröser) Wirkung | |
| DE1793416A1 (de) | Neue Verbindung 1-(4-Amino-3,5-dichlor-phenyl)-2-tert.-butylamino-aethanol | |
| HU205011B (en) | Ultrasonic gel and process for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |